IndustryCompany release

Kiora licenses Senju's oral calpain inhibitor KIO-401 for retinal artery occlusion outside Asia

🇺🇸 Kiora Pharmaceuticals Inc (KPRX) · Thu 29 Oct 2026

The US company will pay $3.5 million upfront for rights to mitucapistat and aims to start a multinational Phase 3 trial in central retinal artery occlusion in 2027.

Kiora Pharmaceuticals announced on 29 October 2026 that it has secured exclusive rights from Senju Pharmaceutical to develop and commercialise KIO-401 (mitucapistat) outside Asia. The product is an oral neuroprotective calpain inhibitor being pursued for central retinal artery occlusion (CRAO).

According to the announcement, KIO-401 has completed Phase 2 and Phase 3 studies in Japan. Kiora has not, in the information available, described the results of those studies.

Under the deal, Kiora will make an upfront payment of $3.5 million. It will also owe a milestone payment in the low teens of millions of dollars, linked to a technology transfer planned for 2027.

Kiora is targeting a multinational Phase 3 trial in CRAO in 2027 and a Phase 2b trial in non-arteritic anterior ischaemic optic neuropathy (NAION) in 2028. Both plans are subject to funding and to regulatory alignment.

The company said it is considering financing options. It has also dropped development of KIO-104, another programme in its pipeline.

What it means for your team

  • Regulatory teams should note that a multinational Phase 3 in 2027 will depend on regulatory alignment, which Kiora has not yet reported as achieved.
  • The 2027 technology transfer is a key milestone: it triggers a payment and will require comparability and manufacturing documentation to support trials outside Japan.
  • Clinical operations and quality groups should expect the development path to depend on Kiora's financing, which remains under consideration.
  • Japanese Phase 2 and 3 data will likely be central to any discussions with Western regulators, though the source gives no detail on those results.

Company's press release (SEC filing): Kiora Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Kiora Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →